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Highlights 
 HBsAg point-of-care tests have slightly lower sensitivities than standard methods. 
 We assessed test characteristics of point-of-care tests using HBsAg mutated viruses. 
 The point-of-care tests accurately diagnosed mutated Hepatitis B viruses. 
 HBsAg mutations do not affect the sensitivity of the evaluated tests. 
*Highlights (for review)
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Abstract 1 
Background: Hepatitis B viruses (HBV) harboring mutations in the a-determinant of the 2 
Hepatitis B surface antigen (HBsAg) are associated with reduced reactivity of HBsAg assays. 3 
Objectives: Evaluating the sensitivity and specificity of three HBsAg point-of-care tests for 4 
the detection of HBsAg of viruses harboring HBsAg mutations. 5 
Study design: A selection of 50 clinical plasma samples containing HBV with HBsAg 6 
mutations was used to evaluate the test characteristics of three HBsAg point-of-care tests 7 
(Vikia®, bioMérieux, Marcy-L`Étoile, France. Alere Determine HBsAg , Iverness Biomedical 8 
Innovations, Köln, Germany. Quick Profile , LumiQuick Diagnostics, California, USA) and 9 
compared to the ARCHITECT HBsAg Qualitative® assay (Abbott Laboratories, Sligo, 10 
Ireland). 11 
Results: The sensitivity of the point-of-care tests ranged from 98% to 100%. The only false-12 
negative result occurred using the Quick Profile  assay with a virus harboring a D144A 13 
mutation. 14 
Conclusions: The evaluated point-of-care tests revealed an excellent sensitivity in detecting 15 
HBV samples harboring HBsAg mutations. 16 
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Background 23 
The mainstay of Hepatitis B virus (HBV) infection diagnosis is the detection of the HBV 24 
surface antigen (HBsAg) [1]. In recent years an increasing number of HBsAg point-of-care 25 
(POC)  tests have become available. POC tests, which use the principle of 26 
immunochromatography as well as enzyme immunoassays and chemiluminescence 27 
immunoassays, are based on the detection of  the antigenic determinant - . 28 
The a-determinant is located between amino acid position 99 and 160 of the HBsAg [2]. 29 
However, in a recent study from The Gambia, POC tests had a slightly lower sensitivity than 30 
the standard serological methods [3] . In diagnostic-escape variants, mutations in the a-31 
determinant of the HBsAg are thought to influence the performance of HBsAg assays [2]. 32 
The diagnostic performance for mutant HBV has been shown to differ across commercial 33 
HBsAg assays, depending on which anti-HBsAg reagents are used [4]. Thus, the different 34 
capacity in detecting HBV diagnostic-escape variants between POC tests and standard 35 
HBsAg assays could be an explanation for the lower sensitivity of POC tests.  36 
Objectives 37 
To determine the performance of three commercial HBsAg POC tests (Vikia®, bioMérieux, 38 
Marcy-L`Étoile, France. Alere Determine HBsAg , Iverness Biomedical Innovations, Köln, 39 
Germany. Quick Profile , LumiQuick Diagnostics, California, USA) in detecting HBV with 40 
HBsAg mutations of the antigenic determinant from clinical samples.  41 
Study Design 42 
We retrospectively screened all samples for HBsAg mutations that were sent to our 43 
reference laboratory for HBV genotyping between January 2010 and December 2013. All 44 
samples with any mutation of the HBsAg with the exception of serotype- (amino acid 45 
positions 122, 127, 140, 159, 160) or genotype- ( T118A, T125M, A128V) specific HBsAg 46 
polymorphisms [5, 6] were considered for this analysis. Twenty randomly selected HBsAg 47 
negative samples were used as negative controls. The HBV viral load was measured using 48 
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COBAS AmpliPrep®/COBAS TaqMan® HBV test 2.0 (Roche Diagnostics, Indianapolis, 49 
USA).  50 
DNA was extracted using NucliSENS easyMAG® (bioMérieux, Paris, France). A fragment of 51 
the HBsAg was amplified in a primary PCR (pPCR) using the primers HBV_1F and HBV_4R 52 
[7]. If needed, a nested PCR (nPCR) was performed using the primers HBV P1F_f and HBV 53 
S6_r [8]. All PCR products were purified using QIAquick® PCR Purification Kit (QIAGEN 54 
GMBH, Hilden, Germany). The purified amplicons were subjected to bidirectional Sanger 55 
sequencing using the primers HBV_1F [5] and HBV S6_r [8] for pPCR products and HBV 56 
P1F_f and HBV S6_r [7, 8] for nPCR products. Cycle sequencing was performed according 57 
to Platt et al [9]. After purification of the cycle sequencing products by the QIAGEN DyeEx® 58 
2.0 Spin Kit (QIAGEN GMBH, Hilden, Germany) The electropherograms were acquired on a 59 
Applied Biosystems® 3130 genetic analyzer (Life Technologies Europe BV, Nieuwerkerk, 60 
Netherlands) and then processed using SeqMan® (DNASTAR Inc., Madison, WI, USA). For 61 
in silico sequence analysis and detection of HBsAg mutations the open access interpretation 62 
tool geno2pheno was used [10].  63 
The performance of three HBsAg POC tests (Vikia®, Alere Determine HBsAg  Quick 64 
Profile )  previously validated in a French cohort [11] was compared with that of the 65 
ARCHITECT HBsAg Qualitative® assay, which has an excellent sensitivity in detecting 66 
HBsAg mutants [12]. False-negative and borderline POC test results were repeated twice. 67 
The ARCHITECT HBsAg Quantitative® assay  was additionally performed in samples with 68 
false-negative POC tests and in samples harboring the same mutations as the false-negative 69 
ones. This allowed determining if false-negative results were caused by lower HBsAg levels. 70 
All tests were performed according to the manufacturer`s instruction.  71 
 72 
Results 73 
Of 153 samples sequenced between 2010 and 2013, 50 contained HBsAg mutations. Forty-74 
one different single or combined mutations were detected (Table 1). With the exception of six 75 
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samples containing the mutations T118S, T126A, T126N, H129L, Y134R or W196L, all 76 
mutant variants had been previously associated with reduced sensitivity for HBsAg detection 77 
[2], occurrence of occult HBV infection [13-15], reduced binding of anti-HBsAg antibodies 78 
[16] or reduced HBsAg secretion [17]. The median HBV viral load was 14`937 IU/ml (IQR 79 
1`139- 329`750 IU/ml). Genotype D was the most prevalent (52.0%, 13/50) followed by A 80 
(26.0%, 13/50), B (10.0%, 5/50), C (6.0%, 3/50), E (4.0%, 2/50) and F (2.0%, 1/50).  81 
The sensitivity and specificity of the HBsAg POC tests were excellent (Table 2). The only 82 
false-negative test occurred using the Quick Profile  assay with a HBV diagnostic escape 83 
variant harboring the single mutation D144A (HBV viral load 432 IU/ml; quantitative HBsAg 84 
140.4 IU/ml). Of note, the Quick Profile  assay produced a borderline positive result using 85 
another sample harboring the mutation F134A/D144A (HBV viral load 603 IU/ml; quantitative 86 
HBsAg 14.8 IU/ml) but was clearly positive for a sample with a D144A/G145A (HBV viral load 87 
41`850`456 IU/ml, quantitative HBsAg 998.7 IU/ml) and a Y100C/Y134H/D144A (HBV viral 88 
load 22`815 IU/ml, quantitative HBsAg 1146.5 IU/ml) mutation. The electropherograms of the 89 
four samples containing a D144A mutation showed single peaks at the amino acid position 90 
144. Therefore the correct identification of viruses harboring the D144A mutation could not 91 
be explained by the presence of non-mutated HBV sub-populations. 92 
Discussion 93 
This is the first study to assess the performance of HBsAg POC tests in diagnosing HBV 94 
harboring HBsAg mutations from clinical samples. We showed that the sensitivity and 95 
specificity of the assays were excellent. One false-negative and one borderline positive test 96 
occurred, both using the Quick Profile  assay. 97 
Bottero et al tested the performance of the identical HBsAg POC tests using whole blood 98 
samples in a large cohort in France [11]. They found high sensitivities (Vikia® 96.5%, Alere 99 
Determine HBsAg  93.6%, Quick Profile  90.5%) and specificities (Vikia® 99.9%, Alere 100 
Determine HBsAg  100%, Quick Profile® 99.7%). Because of the low HBV viral loads in the 101 
samples with false-negative POC test results, they were not able to investigate whether 102 
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false-negatives were caused by HBsAg mutations or by other factors. The sensitivity of POC 103 
tests was even higher in our study, despite analyzing HBV samples harboring HBsAg 104 
mutations. However, we did not have samples with low viral loads, as we only included those 105 
which were successfully sequenced and therefore the sensitivities of the POC test may be 106 
overestimated. We used plasma, which, according to the manufacturer`s information, leads 107 
to a slightly higher sensitivity than whole blood with the Vikia® assay. However, this is not 108 
true for the Alere Determine  - and unknown for the Quick Profile  assay. 109 
In line with findings from Muhlbacher et al, we showed that a specific mutation did not always 110 
have the same effect on the result of the assay [18]. In our study the sample with a single 111 
D144A mutation was not detected by one of the tests, whereas for viruses harboring 112 
additional mutations, the result was either borderline positive or clearly positive. This 113 
phenomenon was not explained by lower quantities of HBsAg in the false-negative sample. 114 
This was the first study to evaluate the sensitivity of HBsAg POC tests for diagnostic escape 115 
mutants using clinical samples with a wide variety of mutations and HBV genotypes. We 116 
recognize that in clinical settings, HBsAg POC tests are generally performed using whole 117 
blood and not serum or plasma. However, in light of recently published evidence, we did not 118 
expect the use of plasma to affect our results significantly [19]. 119 
In conclusion we demonstrated that the three HBsAg POC tests accurately diagnosed 120 
HBsAg diagnostic escape variants in plasma samples. Besides a potentially slightly reduced 121 
performance of the Quick Profile  assay in detecting D144A mutants, our results indicate 122 
that HBsAg mutants do not relevantly affect the sensitivity of the evaluated POC tests.  123 
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Table 1  
HBsAg variants used for test evaluation 
HBsAg mutation (Genotype) n HBsAg mutation (Genotype) n 
Y100C1 (A1) 1 G130N2/T131N2 (D3) 1 
Y100C1/P120T2 (A1) 1 T131I2 (D4) 1 
Y100C1/T118R/P120A /Y134L/D144E2 (D1) 1 T131N2 (B2) 1 
Y100C1/Y134H/D144A2 (D3) 1 T131P2 (D1) 1 
T118K/P120T2 (C2) 1 T131N2/I195M4 (A1) 1 
T118S (D3) 1 M133I2 (A2) 1 
P120L2 (D3) 1 M133L2 (B2, B2) 2 
P120S2 (B4, D2, D3) 3 M133T2 (A1, D4) 2 
P120S2/G145R2 (D3) 1 M133L2/G145A2 (B2) 1 
C124Y2/P135S2 (D1) 1 M133T2/I195M4 (C1) 1 
T126A (A2) 1 Y134R (E) 1 
T126I1 (C2) 1 F134A/D144A2 (D3) 1 
T126N (D3) 1 P135S2 (D4) 1 
T126N/Q129R5 (D1) 1 C139Y2 (D1) 1 
T126N/Q129R5/G145A2 (D1) 1 S143L2 (F2) 1 
H129L (A1) 1 D144A2 (D3) 1 
Q129A/G130R2/T131N2/M133T2/F134V3 (D3) 1 D144A2/G145A2 (D3) 1 
Q129H2/G130R2/T131N2/M133T2/F134V3 (D3) 1 I195M4 (A1, A2, D1, E) 4 
G130N2 (A2) 1 W196L (A1, A2, D3) 3 
G130R2 (D2) 1 W196S4 (A2) 1 
G130R2/T131N2 (D3) 1   
1) Associated with occult HBV [13, 15]  
2) Associated with reduced sensitivity of HBsAg assays [2] 
3) Associated with occult HBV in combination with additional mutations [14] 
4) Associated with reduced binding to anti-HBs antibodies [16]  
5) Asociated with reduced HBsAg secretion [17] 
 
Table
Table 2 
Test characteristics of  HBsAg point-of-care tests compared to CMIA (ARCHITECT HBsAg 
Quantitative assay; Abbott Laboratories, Sligo, Ireland) 
HBsAg serology CMIA Sensitivity Specificity 
positive negative 
VIKIA® (n=50) (n=20) 100% 100% 
  positive 50 0 
  negative 0 20 
DETERMINE  (n=50) (n=20) 100% 100% 
  positive 50 0 
  negative 0 20 
QUICK PROFILE  (n=50) (n=20) 98% 100% 
  positive 49 0 
  negative 1 20 
 
 
Table
